



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: William B. Messer, M.D., Ph.D.

Committee: Vaccines and Related Biological Products Advisory Committee

Meeting Date: March 7, 2019

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: Discuss and make recommendations on the safety and effectiveness of Dengue Tetravalent Vaccine (Live, Attenuated) [Dengvaxia] manufactured by Sanofi Pasteur., I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
N/A	N/A	N/A
II. Other Imputed Interests		
Employer Contract (Current)	Affected Firm ((b) (4))	\$700,000-\$800,000
Employer Contract (Current)	Affected Firm ((b) (4))	\$150,000-\$200,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/s/_____
Signature

February 15, 2019
Date